Tumors topple when ERKs uncouple.
Current antitumor therapies targeting the RAS-ERK pathway have been mostly aimed at inhibiting the activity of the kinases that populate the route. A small-molecule inhibitor of ERK dimerization effectively prevents the progression of tumors harboring oncogenic RAS and BRAF, demonstrating that targeting regulatory protein-protein interactions can be a valid strategy for treating RAS-ERK pathway-driven neoplasia.
Systems Biology Ireland, Conway Institute, University College Dublin , Belfield, Dublin, Ireland.
Ana
A
Herrero
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) , Spain.
Piero
P
Crespo
Antitumor therapy; dimerization inhibitor; ERK